Search Results
Aug 24, 2026, 08:39 ET Leqembi Iqlik® for initiation treatment launched in the US
maintenance treatment of early Alzheimer's disease. In November 2025, a new drug application for subcutaneous formulation of Leqembi was submitted in Japan. In December 2025, Leqembi was included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration
More news about: BioArctic
Aug 24, 2026, 08:35 ET WuXi XDC Delivers Strong First Half 2026 Performance, with Improving Margins and Profitability Further Strengthening Global ADC/XDC CRDMO Leadership
GMP release by the end of August 2026.Future capacities build-out: The XDP5 and XDP6 expansions in Wuxi are designed to augment the Group's drug product manufacturing capacity, reinforcing our ability to support late-stage clinical and commercial-scale programs across diverse modalities, including
More news about: WuXi XDC
Aug 24, 2026, 08:15 ET BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions
NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second
More news about: BrainStorm Cell Therapeutics Inc.
Aug 24, 2026, 08:00 ET Connecticut Office of the Attorney General: If You Bought Certain Generic Prescription Drugs in the United States
generic prescription drug manufacturers in lawsuits alleging that consumers paid artificially inflated prices for generic prescription drugs. The Settling Defendant is Glenmark Pharmaceuticals, Inc., USA. Lawsuits continue against all other Non-Settling Defendant drug manufacturers: Actavis,
More news about: Connecticut Office of the Attorney General
Aug 24, 2026, 08:00 ET Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth
also entered into a strategic cooperation agreement with B. Braun Medical for the exclusive distribution of SeQuent® Please CIS Paclitaxel Drug-Coated Intracranial Balloon Dilatation Catheter in the Chinese mainland. The product is currently under regulatory review for registration and is expected
More news about: Peijia Medical
Aug 24, 2026, 08:00 ET Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
innovative therapies for serious cardiovascular and cardiometabolic diseases. Leveraging its expertise in integrated muscle physiology and small molecule drug development, Edgewise is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy and heart failure.
More news about: Edgewise Therapeutics
Aug 24, 2026, 08:00 ET PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
pediatric population.Interaction with Levodopa: In a 10-year post-marketing safety surveillance program for a non-PKU indication using another drug that is a phenylalanine hydroxylase (PAH) activator, three patients with underlying neurological disorders experienced seizures, exacerbation of seizures,
More news about: PTC Therapeutics, Inc.
Aug 24, 2026, 08:00 ET The9 Reports US$32 Million Net Income for Second Quarter of 2026, Up Over 39% Sequentially
crypto exchanges is approximately US$10 million.The Company's investee Nanyang Biologics Pte. Ltd. ("NYB"), a Singapore-based, AI-driven drug discovery company, has taken a significant step toward its planned Nasdaq listing. At an extraordinary general meeting held on August 19, 2026, shareholders
More news about: The9 Limited
Aug 24, 2026, 08:00 ET Caristo's Technology to be Featured in Non-Contrast CT and Late-Breaking Stroke Prediction Data at ESC 2026
potential applications and are distinct from Caristo's currently available clinical portfolio:CaRi-Heart® has received U.S. Food and Drug Administration (FDA) De Novo marketing authorization and is the first and only technology authorized in the U.S. to quantify coronary inflammation from
More news about: Caristo Diagnostics
Aug 24, 2026, 08:00 ET LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
application has been granted Priority Review designation. Since December 2025, lecanemab (IV) has been included in the "Commercial Insurance Innovative Drug List," recently introduced by the National Healthcare Security Administration (NHSA) of China.LEQEMBI's approvals in these countries
More news about: Eisai Inc.
Aug 24, 2026, 08:00 ET Avulux Granted FDA De Novo Authorization, Creating the First Lens Classification for Migraine-Associated Light Sensitivity
of clinically-proven precision light-filtering lenses for people living with migraine and light sensitivity, today announced that the U.S. Food and Drug Administration (FDA) has granted the company De Novo marketing authorization. The authorization establishes a defined FDA-recognized classification
More news about: Avulux
Aug 24, 2026, 08:00 ET AZENTA ANNOUNCES LEADERSHIP TRANSITION
therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally.
More news about: Azenta
Aug 24, 2026, 07:30 ET Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online
content.About Vector Science & Therapeutics Corp.Vector Science and Therapeutics Corp. (TSXV: PAIN) is a medical technology company advancing drug delivery technology and peptide manufacturing for the sports medicine, regenerative medicine, and pain management markets. The Company's product and
More news about: Vector Sciences & Therapeutics
Aug 24, 2026, 07:24 ET Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
Roche announced that the U.S. Food and Drug Administration (FDA) has cleared the Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test, making it the first and only FDA-cleared single-assay,
More news about: Quest Diagnostics
Aug 24, 2026, 07:15 ET Smart HVAC systems change the way homeowners use energy
all makes and models of heating and cooling equipment. Their technicians are highly trained and qualified and undergo annual background checks, random drug testing, extensive technical and customer service training and are North American Technician Excellence (NATE) certified. Services include HVAC maintenance
More news about: C & C Heating & Air Conditioning
Aug 24, 2026, 07:05 ET REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
protein is structurally identical to normal I2S.RGX-121 has received Orphan Drug Product, Rare Pediatric Disease, Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations from the U.S. Food and Drug Administration and advanced therapy medicinal products (ATMP) classification from
More news about: REGENXBIO Inc.
Aug 24, 2026, 07:02 ET Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings
innovative and comprehensive laboratory services, announced today it will offer the Elecsys® pTau-217 test following clearance by the U.S. Food and Drug Administration (FDA). Developed by Roche Diagnostics, the blood test aids in identifying amyloid pathology associated with Alzheimer's disease in individuals
More news about: Labcorp
Aug 24, 2026, 07:00 ET Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
by dysregulation in the interleukin-36 (IL-36) signaling pathway.1 The US Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare have previously granted Orphan Drug Designation to imsidolimab for the treatment of GPP.
More news about: Vanda Pharmaceuticals Inc.
Aug 24, 2026, 07:00 ET Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care
announced today that the U.S. Food and Drug Administration (FDA) has cleared the Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test, providing clinicians across primary and specialty
More news about: Roche Diagnostics
Aug 24, 2026, 07:00 ET BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
mid- to late-stage investigational medicines — including two approved therapies to treat chronic, debilitating lung diseases — as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around
More news about: Insmed Incorporated
Aug 24, 2026, 07:00 ET Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
agreement covering the broader scope and commercial terms remains under negotiation.The expanded program is intended to support an investigational drug product toward U.S. IND submission and Phase III clinical development.The Company continues to pursue approximately $5 million in CDMO revenues
More news about: Scinai Immunotherapeutics Ltd.
Aug 24, 2026, 06:59 ET Silicone Market worth $33.46 billion by 2031 - Exclusive Report by MarketsandMarkets™
Gold Nanoparticles Market by Process (Physical, Chemical, Biological), Application (Imaging, Targeted Drug Delivery, Proton Therapy, In-Vitro Assays, Sensors, Probes, Catalysis), End-Use Industry and Region - Global Forecast to 2029About MarketsandMarkets™ MarketsandMarkets™
More news about: MarketsandMarkets
Aug 24, 2026, 03:01 ET ImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"
CNS-targeted drug candidates based on the company's platform technologies.Global Partnerships to AccelerateKi-Ho Chang, Co-CEO of ImmunoForge, said, "Through our selection for the Global TIPS R&D program, we plan to further advance the LMT platform and develop new drug peptides with
More news about: ImmunoForge Co., Ltd.
Aug 24, 2026, 02:27 ET Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
data for Deramiocel. The Company failed to secure the FDA's agreement to this change before it resubmitted a Biologics License Application for the drug. Based on these facts, Capricor's public statements were false and materially misleading throughout the class period.If you are a shareholder
More news about: DJS Law Group LLP
Aug 24, 2026, 01:21 ET GC Biopharma's Hunter Syndrome Treatment 'Hunterase' Receives Drug Approval in India and Taiwan
treatment, 'Hunterase IV', has received marketing authorization from India's Central Drugs Standard Control Organisation (CDSCO) and Taiwan's Food and Drug Administration (TFDA). Additionally, 'Hunterase ICV' (brand name in Taiwan: Irifaze ICV), an intracerebroventricular infusion, has also been approved
More news about: GC Biopharma